Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
2型糖尿病中慢性腎病嚴重程度對semaglutide心血管結果的影響:FLOW試驗。
Eur Heart J 2024-08-30
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.
FLOW試驗:一項針對2型糖尿病合併慢性腎臟病患者,使用每週一次semaglutide評估腎臟結果的研究之理念、設計和基線數據。
Nephrol Dial Transplant 2023-12-01
Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis.
Semaglutide對基線腎功能參數不同的2型糖尿病患者及高心血管疾病風險者主要不良心血管事件的影響:SUSTAIN 6和PIONEER 6事後合併分析。
Cardiovasc Diabetol 2023-11-21
Influence of chronic kidney disease and its severity on the efficacy of semaglutide in type 2 diabetes patients: a multicenter real-world study.
慢性腎臟疾病及其嚴重程度對賽馬魯替胰噴酮在第2型糖尿病患者療效的影響:多中心實務研究。
Front Endocrinol (Lausanne) 2023-11-22
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Semaglutide在肥胖和心血管疾病中的SELECT試驗中的長期腎臨床結果。
Nat Med 2024-05-25
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.
在 FLOW 試驗中,Semaglutide 對於合併使用 SGLT2 抑制劑和未合併使用 SGLT2 抑制劑的 2 型糖尿病和慢性腎臟病患者的影響。
Nat Med 2024-06-24
Effects of Once-Weekly Semaglutide on Kidney Disease Outcomes by KDIGO Risk Category in the SUSTAIN 6 Trial.
SUSTAIN 6 試驗中,按 KDIGO 風險類別劑量每週一次的 Semaglutide 對腎病結果的影響。
Kidney Int Rep 2024-07-31
Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?
胰高血糖素樣肽受體-1 受體激動劑:2 型糖尿病和慢性腎病的新興第四支柱?
Med 2024-08-10
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.
FLOW 試驗中 Semaglutide 對糖尿病和慢性腎病心衰竭結果的影響。
J Am Coll Cardiol 2024-09-01